U.S. Affiliate of Growing International Pharmaceutical Organization Signs Agreement with eResearchTechnology Totaling More Than

U.S. Affiliate of Growing International Pharmaceutical Organization Signs
Agreement with eResearchTechnology Totaling More Than $1.1 Million for Cardiac
Safety Monitoring and Information Distribution Services
Study Targets Novel Therapy in Late Phase Development 


PHILADELPHIA, March 10  /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(eRT) , a leading provider of centralized electrocardiographic (ECG) collection
and interpretation services, announced today that it has received an agreement
for more than $1.1 million in cardiac safety monitoring and services from the
U.S. affiliate of a growing international pharmaceutical organization for one of
its drug candidates in late phase clinical development.

The agreement covers a significant Phase III study that will be conducted at 70
sites in the U.S. and Canada.  eRT will provide comprehensive support and 70
units of 12-lead ECG equipment designed to facilitate collection of cardiac
safety data that is subsequently provided to eRT for analysis.eRT will perform
digital collection, measurement, interpretation, review, and distribution of
cardiac safety data through its EXPeRT workflow enabled data handling
technology, the first solution in production that was designed explicitly to
meet emerging international regulatory guidance and technical standards.

"We are pleased to have been awarded this study, which illustrates the effect
that emerging international standards for cardiac safety in new drug development
are having on clinical research across all phases," said Scott Grisanti, senior
vice president of business development and chief marketing officer at eRT. 
"Extensive overall testing in target patient populations and more robust cardiac
safety profiling are combining to drive increasingly large scale digital cardiac
safety collection, management, analysis, and distribution requirements from
pharmaceutical and biotechnology organizations across all geographies and
segments."

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis.  The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development. The company is also
a leader in providing technology and services to streamline the clinical trials
process by enabling its customers to automate the collection, analysis, and
distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. 
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client.  The sponsor may cancel these agreements at its sole discretion.  As a
result, actual results may differ materially from any financial outlooks stated
herein.  Further information on potential factors that could affectthe
company's financial results can be found in the company's Reports on Forms 10-K
and 10-Q filed with the Securities and Exchange Commission. 

DATASOURCE: eResearchTechnology, Inc.



CONTACT:  Joan Sterlacci, eResearchTechnology, Inc., [phone]; or

Matt Hayden, Hayden Communications, [phone], for eResearchTechnology



Web site:  http://www.ert.com/ 

Copyright